Amyloid-targeting therapies (ATTs) substantially reduce amyloid PET signal and slow clinical decline in early symptomatic Alzheimer disease. As ATTs enter clinical practice, PET may assess target engagement and guide treatment management, but there is no consensus on how to measure treatment-related amyloid clearance (...
R. la Joie, M. Lin, Y. Wang et al.· medRxiv· 0 citations
Frontotemporal lobar degeneration (FTLD), predominantly comprised of tau and TDP-43 proteinopathies, is a common cause of early-onset dementia. Biomarkers that reliably classify FTLD subtypes are limited, thereby hindering in-vivo diagnosis and clinical trial stratification. We conducted large-scale, multi-platform cer...
R. Saloner, L. Cornelis, Joshua Downer et al.· bioRxiv· 0 citations
Introduction: Frontotemporal lobar degeneration (FTLD) is a devastating disease that commonly results in early onset dementia, yet its rarity and heterogeneity limit large-scale research and clinical trials. Remote monitoring via low-burden digital health tools may overcome these barriers. We evaluated clinical utility...
E. Paolillo, Sreya Dhanam, J. Taylor et al.· medRxiv· 0 citations
ASL‐derived IF‐perfusion is reduced in AD and may represent a promising imaging marker of altered CSF‐adjacent water transport physiology and further validation against established biomarkers of CSF dynamics and clearance pathways is warranted.
Mona Asghariahmadabad, P. Metanat, Michael Thomas et al.· Annals of Clinical and Trans...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.